ICBP partnership

The partnership includes 24 jurisdictions across 9 countries and 3 continents, including:

• Australia: New South Wales, Queensland, Victoria and Western Australia.
• Canada: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, Quebec and Saskatchewan.
• Denmark
• Ireland
• New Zealand
• Norway
• Sweden (phase 1 only)
• The United Kingdom: England, Northern Ireland, Scotland and Wales.
• The United States (The US Healthcare Delivery Research Program has joined as an associate member for Phase 3. Associate members participate in some of the ICBPs research modules but not the benchmark. They may also not meet all the criteria of full members).
   

All full member Jurisdictions of the ICBP have:

• High quality and long-standing population-based cancer registration with good coverage, to ensure that cancer survival results represent the entire population.
• Primary care led and universal access to health care – for which there will be similar policy considerations.
• Broadly comparable wealth and similar expenditure on healthcare provision.

In Phase 3, we are focusing on 10 cancer sites:

Breast, Colon, Lung, Ovarian, Rectal, Liver, Oesophageal, Pancreas, Stomach, Cervical

The cancer sites studied by the ICBP:

• Include relatively common cancers and cancers where similar challenges are faced across partner countries.

• observed international variation in cancer survival.

• Contribute significantly to overall burden of disease in high-income countries.

ICBP Programme Board

The ICBP is led by the Programme Board, currently chaired by Mark Lawler, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics at Queen’s University Belfast, with support from Deputy Chair David Cameron, Professor of Medical Oncology at the University of Edinburgh. The Programme Board serves as the key decision-making body, meeting quarterly and including funder representatives from each participating jurisdiction. Its diverse expertise—clinical, academic, and policy-focused—ensures a comprehensive and effective approach to ICBP activities.

1-_prof_mark_lawler.jpg ICBP Chair: Mark Lawler

ICBP Committees and Advisory Groups The ICBP has an expert advisory group that reviews outputs, supports translation of the evidence into local contexts and provides advocacy of our research to different audiences. These groups focus on one of three streams: The Advisory Group comprises a ‘core’ group of members who provide Research, Policy, or Clinical advice and is designed to support different aspects of the journey of ICBP research, from scoping and designing research projects, to ensuring clinical expertise are embedded and advocating for policy change. This is complemented by specialist expertise for specific cancer sites, modalities and wider health system understanding for specific pieces of research and application. John Butler, Consultant Gynaecological Oncology Surgeon at the Royal Marsden, is the Lead Clinical Advisor to the ICBP and Chair of the Advisory Group.

ICBP-david_cameron.jpg ICBP Deputy Chair: David Cameron

ICBP Programme Management Team

The Programme Management Team (PMT) have two roles, to facilitate the delivery of all programme activities and to conduct the in-house research. The PMT are hosted by Cancer Research UK, a partner organisation of the ICBP.